Get the Stockscreener App
24.62
7.60%
1.74
After Hours:
25.00
0.38
+1.54%
Mineralys Therapeutics Inc stock is traded at $24.62, with a volume of 1.08M.
It is up +7.60% in the last 24 hours and down -15.77% over the past month.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
See More
Previous Close:
$22.88
Open:
$23.62
24h Volume:
1.08M
Relative Volume:
0.84
Market Cap:
$2.03B
Revenue:
-
Net Income/Loss:
$-154.65M
P/E Ratio:
-10.35
EPS:
-2.3786
Net Cash Flow:
$-142.43M
1W Performance:
+3.01%
1M Performance:
-15.77%
6M Performance:
-36.07%
1Y Performance:
+46.72%
1-Day Range:
$23.59
$24.64
1-Week Range:
$22.42
$24.64
52-Week Range:
$10.44
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
24.62 | 1.89B | 0 | -154.65M | -142.43M | -2.3786 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys reports 2025 results, advances hypertension drug review - MSN
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer By Investing.com - Investing.com Australia
Biopharma Co. Gives New CLO $3.6 Million In Stock Awards - Law360
Mineralys Therapeutics grants inducement equity awards to two new employees - MSN
Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer - TipRanks
Mineralys Grants Inducement Equity Awards to New Employee - MyChesCo
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer - citybiz
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer - Investing.com
Mineralys Therapeutics appoints Jeffrey A. Munsie as chief legal officer - marketscreener.com
Mineralys brings in veteran biotech lawyer as it advances lorundrostat - Stock Titan
Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA AcceptanceWhat's Changed - simplywall.st
Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Earnings Beat: Whats the profit margin of Mineralys Therapeutics IncQuarterly Risk Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Growth Value: What is the implied volatility of Mineralys Therapeutics Inc2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance
Mineralys (MLYS) Q4 2025 Earnings Call Transcript - AOL.com
Why Mineralys Therapeutics Shares Are Sliding Today - TipRanks
Research Analysts Issue Forecasts for MLYS Q1 Earnings - MarketBeat
Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 - Investing.com Canada
Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan
Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares - Stock Titan
Mineralys Reports 2025 Results, Advances Hypertension Drug Review - MyChesCo
Risk Check: Will Mineralys Therapeutics Inc outperform tech stocksTrade Volume Report & Growth-Oriented Investment Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook of MLYS FY2029 Earnings - MarketBeat
Holocene Advisors LP Buys Shares of 1,205,377 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics MLYS CMO sells shares worth $542,973 By Investing.com - Investing.com Canada
Mineralys Therapeutics CMO Sells Over 20,000 Shares - TradingView
Mineralys targets December 2026 lorundrostat approval as payer engagement and data drive launch strategy - MSN
Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety - TipRanks
HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Farallon Capital Management LLC Purchases Shares of 1,673,053 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Cinctive Capital Management LP Has $2.72 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients - MSN
Boothbay Fund Management LLC Increases Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Shares Sold by 22NW LP - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Upgraded to Hold at Wall Street Zen - MarketBeat
Losartan Side Effects You Shouldn’t Ignore—Plus One That May Actually Help - AOL.com
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Suvretta Capital Management LLC - MarketBeat
Integral Health Asset Management LLC Lowers Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (MLYS) makes progress with FDA for hypertension - MSN
Mineralys Therapeutics Charts Path After NDA Acceptance - TipRanks
Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026 - Meyka
David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026 - Stock Titan
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):